HCM
PTLA

Harvey Capital Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Harvey Capital Management’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-150,751
Closed -$3.6M – 88
2019
Q4 		$3.6M Sell
150,751
-1,800
-1% -$49.7K 1.6% 21
2019
Q3 		$4.09M Sell
152,551
-1,800
-1% -$50.5K 2.03% 20
2019
Q2 		$4.19M Sell
154,351
-4,821
-3% -$151K 2.01% 21
2019
Q1 		$5.52M Sell
159,172
-5,500
-3% -$159K 2.65% 13
2018
Q4 		$3.21M Sell
164,672
-20,000
-11% -$411K 1.71% 21
2018
Q3 		$4.92M Buy
184,672
+27,192
+17% +$888K 1.96% 19
2018
Q2 		$5.95M Sell
157,480
-1,100
-0.7% -$42.1K 2.36% 14
2018
Q1 		$5.18M Buy
158,580
+3,000
+2% +$132K 1.94% 22
2017
Q4 		$7.57M Buy
155,580
+11,850
+8% +$599K 2.74% 11
2017
Q3 		$7.76M Sell
143,730
-2,025
-1% -$119K 3.13% 12
2017
Q2 		$8.19M Sell
145,755
-48,625
-25% -$1.95M 3.51% 8
2017
Q1 		$7.62M Sell
194,380
-37,850
-16% -$1.21M 3.42% 10
2016
Q4 		$5.21M Buy
232,230
+48,100
+26% +$940K 2.43% 17
2016
Q3 		$4.18M Sell
184,130
-22,400
-11% -$526K 1.29% 18
2016
Q2 		$4.87M Buy
206,530
+54,850
+36% +$1.35M 2.44% 15
2016
Q1 		$3.09M Sell
151,680
-5,500
-3% -$174K 1.5% 23
2015
Q4 		$8.09M Sell
157,180
-750
-0.5% -$36.4K 3.19% 10
2015
Q3 		$6.73M Buy
157,930
+2,900
+2% +$140K 2.69% 13
2015
Q2 		$7.11M Buy
155,030
+5,350
+4% +$215K 2.41% 15
2015
Q1 		$5.68M Buy
149,680
+13,050
+10% +$448K 2.09% 16
2014
Q4 		$3.87M Buy
136,630
+29,600
+28% +$823K 1.48% 22
2014
Q3 		$2.71M Hold
107,030
– – 1.06% 30
2014
Q2 		$3.12M Buy
107,030
+100
+0.1% +$2.42K 1.12% 27
2014
Q1 		$2.77M Buy
106,930
+63,530
+146% +$1.7M 1.1% 27
2013
Q4 		$1.12M Buy
+43,400
New +$1.05M 0.46% 43

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Harvey Capital Management's PTLA Position: Q1 2020 in Review

Harvey Capital Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q1 2020, closing a stake of 150,751 shares — an estimated $3.6M sold.

Harvey Capital Management first reported a position in PTLA in Q4 2013 and held it in 25 quarters. The position peaked at $8.19M in Q2 2017. 187 funds tracked by Wall St. Rank hold PTLA as of Q1 2020.

  • Harvey Capital Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • Harvey Capital Management sold 150,751 Portola Pharmaceuticals, Inc. shares in Q1 2020, an estimated $3.6M.
  • Harvey Capital Management first reported a position in Portola Pharmaceuticals, Inc. in Q4 2013 and held it in 25 quarters.
  • Harvey Capital Management's Portola Pharmaceuticals, Inc. position peaked at $8.19M in Q2 2017.
  • 187 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q1 2020.

Based on Harvey Capital Management's 13F filing for Q1 2020, filed 29 Apr 2020.